These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 24565676)
1. Tamoxifen compared to best supportive care in advanced hepatocelluar carcinoma: A retrospective matched-cohort study. Zeeneldin AA; Eid SM; Darweesh AD; Moneer MM; Saadeldin M J Egypt Natl Canc Inst; 2014 Mar; 26(1):1-7. PubMed ID: 24565676 [TBL] [Abstract][Full Text] [Related]
2. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience. Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677 [TBL] [Abstract][Full Text] [Related]
3. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy. Estfan B; Byrne M; Kim R Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010 [TBL] [Abstract][Full Text] [Related]
5. The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib. Chen L; Su H; Shao H; Xu K; Liang S; Liu J Hepatogastroenterology; 2014 May; 61(131):802-8. PubMed ID: 26176077 [TBL] [Abstract][Full Text] [Related]
6. Untreated hepatocellular carcinoma in Egypt: outcome and prognostic factors. Zeeneldin AA; Salem SE; Darwish AD; El-Gammal MM; Hussein MM; Saadeldin M J Hepatocell Carcinoma; 2015; 2():3-9. PubMed ID: 27508189 [TBL] [Abstract][Full Text] [Related]
7. Clinical parameters predictive of outcomes in sorafenib-treated patients with advanced hepatocellular carcinoma. Cho JY; Paik YH; Lim HY; Kim YG; Lim HK; Min YW; Gwak GY; Choi MS; Lee JH; Koh KC; Paik SW; Yoo BC Liver Int; 2013 Jul; 33(6):950-7. PubMed ID: 23601249 [TBL] [Abstract][Full Text] [Related]
8. Advanced hepatocellular carcinoma: A regional cancer center experience of 48 cases. Lokesh KN; Chaudhuri T; Lakshmaiah KC; Babu KG; Dasappa L; Jacob LA; Suresh Babu MC; Rudresha AH; Rajeev LK Indian J Cancer; 2017; 54(3):526-529. PubMed ID: 29798951 [TBL] [Abstract][Full Text] [Related]
9. Sorafenib in liver function impaired advanced hepatocellular carcinoma. Ji YX; Zhang ZF; Lan KT; Nie KK; Geng CX; Liu SC; Zhang L; Zhuang XJ; Zou X; Sun L; Zhang ZC Chin Med Sci J; 2014 Mar; 29(1):7-14. PubMed ID: 24698672 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase II study of axitinib versus placebo plus best supportive care in second-line treatment of advanced hepatocellular carcinoma. Kang YK; Yau T; Park JW; Lim HY; Lee TY; Obi S; Chan SL; Qin S; Kim RD; Casey M; Chen C; Bhattacharyya H; Williams JA; Valota O; Chakrabarti D; Kudo M Ann Oncol; 2015 Dec; 26(12):2457-63. PubMed ID: 26386123 [TBL] [Abstract][Full Text] [Related]
11. Response of negative estrogen-receptor hepatocarcinoma to tamoxifen, and survival of non-resectable patients. García-Leiva J; Gamboa-Domínguez A; Ceron-Lizarraga T; Morales-Espinosa D; Meza-Junco J; Arrieta O Ann Hepatol; 2006; 5(4):263-7. PubMed ID: 17151578 [TBL] [Abstract][Full Text] [Related]
13. Prognostic factors in patients with advanced hepatocellular carcinoma treated with sorafenib. Pinter M; Sieghart W; Hucke F; Graziadei I; Vogel W; Maieron A; Königsberg R; Weissmann A; Kornek G; Matejka J; Stauber R; Buder R; Grünberger B; Schöniger-Hekele M; Müller C; Peck-Radosavljevic M Aliment Pharmacol Ther; 2011 Oct; 34(8):949-59. PubMed ID: 21883324 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma: age is not a problem. Ziogas DC; Papadatos-Pastos D; Thillai K; Korantzis I; Chowdhury R; Suddle A; O'Grady J; Al-Khadimi G; Allen N; Heaton N; Ross PJ; Sarker D Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):48-55. PubMed ID: 27623000 [TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of a cohort of 63 patients with hepatocellular carcinoma treated with octreotide. Rabe C; Pilz T; Allgaier HP; Halm U; Strasser C; Wettstein M; Sauerbruch T; Caselmann WH Z Gastroenterol; 2002 Jun; 40(6):395-400. PubMed ID: 12055662 [TBL] [Abstract][Full Text] [Related]
16. Randomized Phase II Study of the X-linked Inhibitor of Apoptosis (XIAP) Antisense AEG35156 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC). Lee FA; Zee BC; Cheung FY; Kwong P; Chiang CL; Leung KC; Siu SW; Lee C; Lai M; Kwok C; Chong M; Jolivet J; Tung S Am J Clin Oncol; 2016 Dec; 39(6):609-613. PubMed ID: 24977690 [TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of sorafenib versus best supportive care in advanced hepatocellular carcinoma in Egypt. Hamdy Elsisi G; Nada Y; Rashad N; Carapinha J J Med Econ; 2019 Feb; 22(2):163-168. PubMed ID: 30479174 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Ogasawara S; Chiba T; Ooka Y; Kanogawa N; Motoyama T; Suzuki E; Tawada A; Kanai F; Yoshikawa M; Yokosuka O Oncology; 2014; 87(6):330-41. PubMed ID: 25227534 [TBL] [Abstract][Full Text] [Related]
19. Gemcitabine plus oxaliplatin in advanced hepatocellular carcinoma: a large multicenter AGEO study. Zaanan A; Williet N; Hebbar M; Dabakuyo TS; Fartoux L; Mansourbakht T; Dubreuil O; Rosmorduc O; Cattan S; Bonnetain F; Boige V; Taïeb J J Hepatol; 2013 Jan; 58(1):81-8. PubMed ID: 22989572 [TBL] [Abstract][Full Text] [Related]
20. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas. Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]